Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis.
Journal
HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
31
08
2020
revised:
12
11
2020
accepted:
24
11
2020
pubmed:
26
1
2021
medline:
27
1
2022
entrez:
25
1
2021
Statut:
ppublish
Résumé
Access to health insurance and curative interventions [surgery/liver-directed-therapy (LDT)] affects survival for early-stage hepatocellular carcinoma (HCC). The aim of this multi-institutional study of high-volume safety-net hospitals (SNHs) and their tertiary-academic-centers (AC) was to identify the impact of type/lack of insurance on survival disparities across hospitals, particularly SNHs whose mission is to minimize insurance related access-to-care barriers for vulnerable populations. Early-stage HCC patients (2012-2014) from the US Safety-Net Collaborative were propensity-score matched by treatment at SNH/AC. Overall survival (OS) was the primary outcome. Multivariable Cox proportional-hazard analysis was performed accounting for sociodemographic/clinical parameters. Among 925 patients, those with no insurance (NI) had decreased curative surgery, compared to those with government insurance (GI) and private insurance [PI, (PI-SNH:60.5% vs. GI-SNH:33.1% vs. NI-SNH:13.6%, p < 0.001)], and decreased median OS (PI-SNH:32.1 vs. GI-SNH:22.8 vs. NI-SNH:9.4 months, p = 0.002). On multivariable regression controlling for sociodemographic/clinical parameters, NI-SNH (HR:2.5, 95% CI:1.3-4.9, p = 0.007) was the only insurance type/hospital system combination with significantly worse OS. NI-SNH patients received less curative treatment than other insurance/hospitals types suggesting that treatment barriers, beyond access-to-care, need to be identified and addressed to achieve survival equity in early-stage HCC for vulnerable populations (NI-SNH).
Sections du résumé
BACKGROUND
Access to health insurance and curative interventions [surgery/liver-directed-therapy (LDT)] affects survival for early-stage hepatocellular carcinoma (HCC). The aim of this multi-institutional study of high-volume safety-net hospitals (SNHs) and their tertiary-academic-centers (AC) was to identify the impact of type/lack of insurance on survival disparities across hospitals, particularly SNHs whose mission is to minimize insurance related access-to-care barriers for vulnerable populations.
METHODS
Early-stage HCC patients (2012-2014) from the US Safety-Net Collaborative were propensity-score matched by treatment at SNH/AC. Overall survival (OS) was the primary outcome. Multivariable Cox proportional-hazard analysis was performed accounting for sociodemographic/clinical parameters.
RESULTS
Among 925 patients, those with no insurance (NI) had decreased curative surgery, compared to those with government insurance (GI) and private insurance [PI, (PI-SNH:60.5% vs. GI-SNH:33.1% vs. NI-SNH:13.6%, p < 0.001)], and decreased median OS (PI-SNH:32.1 vs. GI-SNH:22.8 vs. NI-SNH:9.4 months, p = 0.002). On multivariable regression controlling for sociodemographic/clinical parameters, NI-SNH (HR:2.5, 95% CI:1.3-4.9, p = 0.007) was the only insurance type/hospital system combination with significantly worse OS.
CONCLUSION
NI-SNH patients received less curative treatment than other insurance/hospitals types suggesting that treatment barriers, beyond access-to-care, need to be identified and addressed to achieve survival equity in early-stage HCC for vulnerable populations (NI-SNH).
Identifiants
pubmed: 33487553
pii: S1365-182X(20)32396-0
doi: 10.1016/j.hpb.2020.11.1150
pmc: PMC8205960
mid: NIHMS1665720
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
868-876Subventions
Organisme : NCI NIH HHS
ID : K12 CA226330
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA211034
Pays : United States
Informations de copyright
Copyright © 2021 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Références
J Clin Gastroenterol. 2018 May/Jun;52(5):437-443
pubmed: 28723861
J Clin Gastroenterol. 2016 Mar;50(3):258-65
pubmed: 26352107
J Hepatocell Carcinoma. 2019 Nov 15;6:167-181
pubmed: 31815112
Ann Surg Oncol. 2010 Dec;17(12):3104-11
pubmed: 20585872
J Viral Hepat. 2015 Sep;22(9):727-36
pubmed: 25581816
J Am Coll Surg. 2020 Mar 3;:
pubmed: 32272206
Ann Surg. 2018 Oct;268(4):584-590
pubmed: 30004928
PeerJ. 2019 Jan 11;6:e6231
pubmed: 30648004
Dig Dis Sci. 2019 Apr;64(4):910-917
pubmed: 30835028
Gastroenterology. 2020 May;158(6):1822-1830
pubmed: 32006545
J Am Coll Surg. 2019 Apr;228(4):342-353.e1
pubmed: 30802505
Cancer. 2020 Jul 15;126(14):3303-3311
pubmed: 32294251
JAMA Netw Open. 2020 Feb 5;3(2):e1921653
pubmed: 32074294
Cancer. 2016 Aug 15;122(16):2512-23
pubmed: 27195481
Int J Environ Res Public Health. 2017 Jun 13;14(6):
pubmed: 28608826
J Am Acad Orthop Surg. 2020 Jun 1;28(11):464-470
pubmed: 32287086
CA Cancer J Clin. 2008 Jan-Feb;58(1):9-31
pubmed: 18096863
Inquiry. 2018 Jan-Dec;55:46958018796361
pubmed: 30188235
J Health Commun. 2016;21 Suppl 1:43-50
pubmed: 27043757
Liver Cancer. 2015 Mar;4(1):70-83
pubmed: 26020030
Med Care. 2020 Feb;58(2):183-191
pubmed: 31934958
J Pediatr Hematol Oncol. 2014 Jan;36(1):51-6
pubmed: 24136028
Cancer Res Treat. 2020 Oct;52(4):1145-1152
pubmed: 32599989
J Clin Exp Hepatol. 2020 Jan-Feb;10(1):43-80
pubmed: 32025166
Cancer. 2020 Feb 15;126(4):775-781
pubmed: 31714593
Ann Hepatol. 2019 May - Jun;18(3):461-465
pubmed: 31040093
HPB (Oxford). 2015 Sep;17(9):747-52
pubmed: 26278321
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S40-S48
pubmed: 30670200
Public Health Rep. 2017 May/Jun;132(3):316-325
pubmed: 28358997
JAMA Oncol. 2020 Mar 1;6(3):385-392
pubmed: 31917398
J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15
pubmed: 10451447
Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):300-307
pubmed: 31796525
Hepatology. 2015 Jan;61(1):191-9
pubmed: 25142309
JAMA Otolaryngol Head Neck Surg. 2018 Nov 1;144(11):1052-1057
pubmed: 30242321
World J Hepatol. 2015 Mar 27;7(3):406-24
pubmed: 25848467
BMC Health Serv Res. 2015 Sep 10;15:371
pubmed: 26357948
Cancer. 2017 Apr 1;123(7):1219-1227
pubmed: 27859019
Cancer. 2017 Aug 15;123(16):3125-3131
pubmed: 28440864
HPB Surg. 2011;2011:818217
pubmed: 21760664
J Carcinog. 2017 May 29;16:1
pubmed: 28694740